Phase II Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Patients With Advanced Solid Tumors (KEYNOTE 158),
The purpose of this phase II trial is to evaluate the efficacy of pembrolizumab in patients with select solid tumors, including pancreatic cancer, that have experienced disease progression after receiving standard of care treatment.
Study ID: 3475-158
Trial Phase: Phase II
Trial Sponsor: Merck Sharp & Dohme Corp.
Therapies Used in This Trial: Pembrolizumab